Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Equity Average (2021 - 2026)

bioAffinity Technologies has reported Equity Average over the past 5 years, most recently at $5.5 million for Q1 2026.

  • Quarterly Equity Average rose 170.67% to $5.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $5.5 million through Mar 2026, up 170.67% year-over-year, with the annual reading at $4.9 million for FY2025, 32.48% up from the prior year.
  • Equity Average was $5.5 million for Q1 2026 at bioAffinity Technologies, down from $8.1 million in the prior quarter.
  • Over five years, Equity Average peaked at $11.8 million in Q4 2022 and troughed at -$16.8 million in Q2 2022.
  • The 5-year median for Equity Average is $4.3 million (2024), against an average of $2.6 million.
  • Year-over-year, Equity Average soared 460.38% in 2023 and then tumbled 108.02% in 2025.
  • A 5-year view of Equity Average shows it stood at $11.8 million in 2022, then tumbled by 49.88% to $5.9 million in 2023, then plummeted by 51.7% to $2.9 million in 2024, then surged by 182.71% to $8.1 million in 2025, then tumbled by 32.39% to $5.5 million in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Equity Average are $5.5 million (Q1 2026), $8.1 million (Q4 2025), and $3.4 million (Q3 2025).